<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380805</url>
  </required_header>
  <id_info>
    <org_study_id>AK104-201-AU</org_study_id>
    <nct_id>NCT04380805</nct_id>
  </id_info>
  <brief_title>A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer</brief_title>
  <official_title>A Phase 2, Multicenter, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of AK104 in Subjects With Recurrent or Metastatic Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akesobio Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the&#xD;
      efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy&#xD;
      in adult subjects with previously treated recurrent or metastatic cervical carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) assessed by Independent Radiological Review Committee (IRRC)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR assessed by Investigator</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>From the time of informed consent signed through 30 days after the last dose, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed concentration (Cmin) of AK104 at steady state</measure>
    <time_frame>From first dosing date of AK104 through 30 days post last dose of AK104, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies</measure>
    <time_frame>From first dosing date of AK104 through 90 days post last dose of AK104, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Cervical Cancer</condition>
  <condition>Metastatic Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>AK104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK104 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AK104</intervention_name>
    <description>All subjects will receive AK104 as a single agent at a dose of 6 mg/kg Q2W (Day 1 and Day 15 of each 28 day treatment cycle) via IV infusion.</description>
    <arm_group_label>AK104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide written and signed informed consent and any locally required&#xD;
             authorization obtained from the subject/legal representative.&#xD;
&#xD;
          2. Women aged ≥18 years at the time of study entry.&#xD;
&#xD;
          3. Subjects must have histologically or cytologically confirmed recurrent or metastatic&#xD;
             squamous carcinoma or adenosquamous carcinoma of the cervix, and meet the following&#xD;
             criteria: disease progression confirmed by radiologic imaging during or following&#xD;
             prior platinum based doublet chemotherapy, with or without bevacizumab for recurrent&#xD;
             or metastatic cervical cancer; No more than 2 prior systemic therapies in the&#xD;
             recurrent or metastatic setting.&#xD;
&#xD;
          4. Subjects must have measurable lesions according to RECIST v1.1. The presence of&#xD;
             measurable lesions must be confirmed by the IRRC. A previously irradiated lesion is&#xD;
             not considered measurable and cannot be selected as a target lesion.&#xD;
&#xD;
          5. Available archived tumor tissue sample - block or a minimum of 10 unstained slides of&#xD;
             formalin fixed paraffin embedded [FFPE] tissues - preferably from the most recent&#xD;
             biopsy of a tumor lesion collected either at the time of or after the diagnosis of&#xD;
             locally advanced, recurrent, and/or metastatic disease has been made.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.&#xD;
&#xD;
          7. Life expectancy ≥12 weeks.&#xD;
&#xD;
          8. Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent enrollment in another clinical study, unless it is an observational&#xD;
             (noninterventional) clinical study or the follow-up period of an interventional study.&#xD;
&#xD;
          2. Histological types of cervical cancer other than squamous carcinoma and adeno-squamous&#xD;
             carcinoma (eg, adenocarcinoma, small cell carcinoma, clear cell carcinoma, sarcoma,&#xD;
             etc).&#xD;
&#xD;
          3. Prior malignancy active within the previous 2 years except for the tumor for which a&#xD;
             subject is enrolled in the study, and locally curable cancers that have been&#xD;
             apparently cured, such as basal cell skin cancer, or carcinoma in situ of the breast.&#xD;
&#xD;
          4. Brain/central nervous system (CNS) metastases.&#xD;
&#xD;
          5. Clinically significant hydronephrosis, as determined by the investigator, not&#xD;
             alleviated by nephrostomy or ureteral stent&#xD;
&#xD;
          6. Active infections (including tuberculosis) requiring systemic antibacterial,&#xD;
             antifungal, or antiviral therapy within 4 weeks prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
          7. Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             active acquired immunodeficiency syndrome.&#xD;
&#xD;
          8. Known active hepatitis B or C infections (known positive hepatitis B surface antigen&#xD;
             [HBsAg] result or positive hepatitis C virus [HCV] antibody with detectable HCV&#xD;
             ribonucleic acid [RNA] results).&#xD;
&#xD;
          9. Active or prior documented autoimmune disease that may relapse.&#xD;
&#xD;
         10. History of interstitial lung disease or noninfectious pneumonitis, except for those&#xD;
             induced by radiation therapies.&#xD;
&#xD;
         11. Patients with clinically significant cardio-cerebrovascular disease.&#xD;
&#xD;
         12. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to&#xD;
             NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with&#xD;
             the exception of toxicities not considered a safety risk.&#xD;
&#xD;
         13. History of severe hypersensitivity reactions to other mAbs.&#xD;
&#xD;
         14. Prior allogeneic stem cell transplantation or organ transplantation.&#xD;
&#xD;
         15. Known allergy or reaction to any component of the AK104 formulation.&#xD;
&#xD;
         16. Receipt of the following treatments or procedures: anticancer small molecule targeted&#xD;
             agent within 2 weeks, radiation therapy within 2 weeks, other anticancer therapy&#xD;
             within 4 weeks, any major surgery within 4 weeks, any other investigational product or&#xD;
             procedure within 4 weeks, or agents with immunomodulatory effect within 2 weeks prior&#xD;
             to the first dose of investigational product.&#xD;
&#xD;
         17. Subjects with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily doses of prednisone or equivalent) or other immunosuppressive&#xD;
             medications within 14 days prior to the first dose of investigational product.&#xD;
&#xD;
         18. Receipt of live attenuated vaccines within 30 days prior to the first dose of&#xD;
             investigational product.&#xD;
&#xD;
         19. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell&#xD;
             costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).&#xD;
&#xD;
         20. Any condition that, in the opinion of the Investigator, would interfere with&#xD;
             evaluation of the investigational product or interpretation of subject safety or study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Randall, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kon Yew Kwek, BMBCh, DPhil</last_name>
    <phone>+86 (0760) 8987 3999</phone>
    <email>global.trials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Womens Cancer Research Foundation</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica King, Research Director</last_name>
      <phone>949-642-5165</phone>
      <email>mking@goapartners.com</email>
    </contact>
    <investigator>
      <last_name>John Micha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Oncology &amp; Hematology Consultants</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Reyes</last_name>
      <phone>561-447-0614</phone>
      <email>vreyes@brcrglobal.com</email>
    </contact>
    <investigator>
      <last_name>Harshard Amin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharad Ghamande</last_name>
      <phone>706-721-8978</phone>
      <email>dwheatley@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Sharad Ghamande</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology (Plum Orchard)</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jade Kaye Lee</last_name>
      <phone>301-933-3216</phone>
      <email>jadekaye.lee@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Frederick Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Blavatnik Family - Chelsea Medical Center at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Ruiz</last_name>
      <phone>212-367-1863</phone>
      <email>meghan.ruiz@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Emma Brown</last_name>
      <phone>212-824-7049</phone>
      <email>emma.brown@mssm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Blank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Veena John, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyvona White</last_name>
      <phone>513-751-2273</phone>
      <email>jyvona.white@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <phone>918-505-3201</phone>
      <phone_ext>4075</phone_ext>
      <email>melissa.powell@ocsri.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga's Program In Women's Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Donelson</last_name>
      <phone>423-266-3636</phone>
      <email>kimberly.donelson@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Stephen DePasquale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Erika Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lonnese Taylor</last_name>
      <phone>214-648-7094</phone>
      <email>lonnese.taylor@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Morris</last_name>
      <phone>817-413-1647</phone>
      <email>tina.morris@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Noelle Cloven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyndon B. Johnson Hospital (MD Anderson)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaby Granda</last_name>
      <phone>713-745-8318</phone>
      <email>jggranda@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Michaela Onstad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology (Woodlands)</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>713-242-3500</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Marks</last_name>
      <phone>757-213-5805</phone>
      <email>jenny.marks@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael McCollum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Washington</last_name>
      <phone>804-628-2582</phone>
      <email>slwashington@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Randall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Gynecology Specialists, P. C.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leah Clemente</last_name>
      <phone>206-215-2397</phone>
      <email>leah.clemente@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Charles Drescher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophia Frentzas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tarek Meniawy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meena Okera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bo Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICON Cancer Centre</name>
      <address>
        <city>Brisbane</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeffrey Goh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michelle Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

